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Glycodelin is a human glycoprotein with 1 
four reported glycoforms, namely glycodelin-A 2 
(GdA), glycodelin-F (GdF), glycodelin-C (GdC) 3 
and glycodelin-S (GdS). These glycoforms have 4 
the same protein core and appear to differ in 5 
their N-glycosylation. The glycosylation of GdA is 6 
completely different from that of GdS. GdA 7 
inhibits proliferation and induces cell death of 8 
T-cells. However, the glycosylation and 9 
immuno-modulating activities of GdF and GdC 10 
are not known. This study aimed to use ultra-high 11 
sensitivity mass spectrometry to compare the 12 
glycomes of GdA, GdC and GdF, and to study the 13 
relationship between the immunological activity 14 
and glycosylation pattern among glycodelin 15 
glycoforms. Using MALDI-TOF strategies, the 16 
glycoforms were shown to contain an enormous 17 
diversity of bi-, tri- and tetra-antennary 18 
complex-type glycans carrying Galβ1-4GlcNAc 19 
(lacNAc) and/or GalNAcβ1-4GlcNAc (lacdiNAc) 20 
antennae backbones with varying levels of fucose 21 
and sialic acid substitution. Interestingly, they all 22 
carried a family of Sda 23 
(NeuAcα2-3(GalNAcβ1-4)Gal)-containing glycans 24 
which were not identified in the earlier study 25 
because of less sensitive methodologies used. 26 
Among the three glycodelins, GdA is most heavily 27 
sialylated. Virtually all the sialic acid on GdC 28 
occurs on the Sda antennae. With the exception 29 
of the Sda epitope, the GdC N-glycome appears 30 
to be the asialylated counterpart of the GdA/GdF 31 
glycomes. Sialidase activity, which may be 32 
responsible for transforming GdA/GdF to GdC, 33 
was detected in cumulus cells. Both GdA and GdF 34 
inhibited the proliferation, induced cell death and 35 
suppressed IL-2 secretion of Jurkat cells and 36 
peripheral blood mononuclear cells. In contrast, 37 
no immunosuppressive effect was observed for 38 
GdS and GdC.  39 
 40 
Glycodelin is a member of the lipocalin family. 41 
It consists of 180 amino acid residues (1) with two 42 
sites of N-linked glycosylation. There are four 43 
reported glycodelin isoforms, namely glycodelin-A 44 
(amniotic fluid isoform, GdA), glycodelin-F 45 
(follicular fluid, GdF), glycodelin-C (cumulus 46 
matrix, GdC) and glycodelin-S (seminal plasma, 47 
GdS) (2-5). Among the four glycodelin isoforms, 48 
only the N-glycan structures of GdA and GdS have 49 
been previously determined. This was achieved 50 
using fast atom bombardment mass spectrometry 51 
(6,7). The glycan structures of GdA and GdS are 52 
completely different. In GdA, the Asn-28 site carries 53 
high mannose, hybrid and complex-type structures, 54 
whereas the second Asn-63 site is exclusively 55 
occupied by complex-type glycans (6). The major 56 
non-reducing epitopes characterised in the 57 
complex-type glycans are Galβ1-4GlcNAc (lacNAc), 58 
GalNAcβ1-4GlcNAc (lacdiNAc), 59 
NeuAcα2-6Galβ1-4GlcNAc (sialylated lacNAc), 60 
NeuAcα2-6GalNAcβ1-4GlcNAc (sialylated 61 
lacdiNAc), Galβ1-4(Fucα1-3)GlcNAc (Lewis-x) and 62 
GalNAcβ1-4(Fucα1-3)GlcNAc (lacdiNAc analog of 63 
the blood group substance Lewis-x) (6). Many of 64 
these oligosaccharides are rare in other human 65 
glycoproteins. GdS glycans are unusually fucose 66 
rich, and the major complex type glycan structures 67 
are bi-antennary glycans with Lewis-x and Lewis-y 68 
antennae. Glycosylation of GdS is highly 69 
site-specific. Asn-28 contains only high mannose 70 
 2 
structures, while Asn-63 contains only complex type 1 
glycans. More than 80% of the complex glycans 2 
have 3-5 fucose residues/glycan, and none of the 3 
glycans is sialylated, which is unusual for a secreted 4 
human glycoprotein (7). The glycan structures of 5 
GdF and GdC are not known, though they differ in 6 
lectin binding properties and isoelectric point from 7 
the other two glycodelin isoforms (5).  8 
Glycans are involved in various intracellular, 9 
intercellular and cell-matrix recognition events (8,9). 10 
Glycosylation determines the biological activities of 11 
the glycodelin isoforms (2,10). For example, both 12 
GdA and GdF inhibit the spermatozoa-zona 13 
pellucida binding (11) via fucosyltransferase-5 (12), 14 
but only the latter inhibits progesterone-induced 15 
acrosome reaction, thus preventing a premature 16 
acrosome reaction of the spermatozoa. There is 17 
evidence that cumulus cells can convert exogenous 18 
GdA and -F to GdC, the physicochemical properties 19 
of which suggest that it is differently glycosylated 20 
compared with GdA/F (5). Moreover, GdC 21 
stimulated spermatozoa-zona pellucida binding in a 22 
dose-dependent manner and it effectively displaced 23 
sperm-bound GdA and -F (4,5). GdS suppresses 24 
capacitation probably via its inhibitory activity on 25 
cholesterol efflux from spermatozoa (13). 26 
Except for the effects on fertilization, GdA is 27 
involved in feto-maternal defense. This glycodelin 28 
isoform suppresses proliferation and induces 29 
apoptosis of T-cells (2), and also inhibits natural 30 
killer cell (14) and B-cell activities (15). 31 
Glycosylation is involved in the binding of GdA to 32 
receptors on T-cells (16). The sialic acid of GdA 33 
contributes to the apoptotic activity in T-cells (17,18) 34 
and binding to CD45, a potential GdA receptor (16). 35 
The importance of glycosylation in glycodelin is 36 
further shown by the absence of immunosuppressive 37 
activities in GdS with different glycosylation (18). 38 
The immuno-modulating activities of GdF and GdC 39 
are unknown.  40 
Our previous work showed that glycans are 41 
indispensable for the different glycodelins to exhibit 42 
their binding activities and biological effects 43 
(13,19,20). The present study aims at identifying the 44 
effect of all four glycodelin isoforms on lymphocyte 45 
viability, cell death, and interleukin-2 (IL-2) 46 
secretion and to correlate these bioactivities with 47 
their glycosylation patterns determined by mass 48 
spectrometry. 49 
 50 
EXPERIMENTAL PROCEDURES 51 
 52 
Preparation of peripheral blood mononuclear cells 53 
(PBMCs)- Human peripheral blood from healthy 54 
female donors was obtained from the Hong Kong 55 
Red Cross blood transfusion service. PBMCs were 56 
isolated from the buffy coat by Ficoll-Paque density 57 
gradient centrifugation (GE Healthcare, Uppsala, 58 
Sweden). In brief, diluted buffy coat (1:1 with 59 
phosphate buffer saline, PBS, pH 7.2) was layered 60 
on the Ficoll and centrifuged at 400 g for 40 minutes 61 
at room temperature. The remaining red blood cells 62 
were removed using red blood cell lysing buffer 63 
(150mM NH4Cl, 10mM NaHCO3, 0.1mM EDTA). 64 
The PBMCs were then washed twice with PBS and 65 
resuspended in RPMI medium containing 10% fetal 66 
bovine serum (FBS), 50 units/ml of penicillin and 50 67 
μg/ml of streptomycin. Monocytes were removed by 68 
cell adhesion in plastic culture flask for 2 hours.  69 
Cell cultures- PBMCs and human cell lines 70 
including oviductal cells (OE E6/E7), natural killer 71 
cells (NK92mi), cells from a chronic myelogenous 72 
leukaemia line (K562), T-lymphoma cells (Jurkat), 73 
hepato-carcinoma cells (Hela), trophoblast 74 
choriocarcinoma cells (BeWo) and endometrial cells 75 
(RL95) were cultured in RPMI 1640 (K562, Jurkat, 76 
PBMCs), DMEM (Hela, OE E6/E7, BeWo and 77 
RL95) or MEM (NK92mi) supplemented with 10% 78 
fetal bovine serum, 50 units/ml of penicillin and 50 79 
μg/ml of streptomycin at 37oC in an atmosphere of 80 
5% CO2 in air. 81 
Purification of glycodelins- The study protocol was 82 
approved by the Institutional Review Board of the 83 
University of Hong Kong/Hospital Authority Hong 84 
Kong West Cluster. GdA, -S, -F and -C were 85 
purified as described from first trimester amniotic 86 
fluid, seminal plasma, follicular fluid, and cumulus 87 
matrix of human, respectively (5,12,19) at Queen 88 
Mary Hospital, Hong Kong. The collected samples 89 
were diluted with tris-buffered saline (TBS, pH 7.4) 90 
and 0.1% Triton X-100 in a ratio of 1:3-1:5 was 91 
added. GdA, -S and -C were purified by monoclonal 92 
anti-glycodelin (clone F43-7F9) chromatography. In 93 
brief, the diluted amniotic fluid, seminal plasma or 94 
cumulus matrix were loaded onto anti-glycodelin 95 
column, which was then washed successively by 96 
TBS, 1M NaCl with 1% isopropanol, 10 mM 97 
ammonium acetate with 0.1% isoproponal, pH 5 and 98 
TBS. Glycodelin was eluted by 20 mM CaCl2 with 99 
0.1% trifluoroacetic acid. The eluted GdS and -C 100 
were further purified with anion-exchange Mono-Q 101 
(GE Healthcare) column by AKTA purifier 10 (GE 102 
Healthcare). The purification of GdF involved the 103 
successively use of several chormatographic 104 
columns including Hi-trap blue, protein-G, lectin 105 
affinity, Mono-Q and gel filtration as described (21). 106 
The purified glycodelins were dialyzed in 2 mM 107 
Tris-HCl, pH 7.5 and concentrated by Amicon-10 108 
concentrator (Amicon Inc., Billerica, USA). 109 
Deglycosylated glycodelin was prepared by 110 
denaturation of GdA in 0.1% β-mecaptoethanol 111 
before incubation with 0.5 mU PNGase F at 37°C 112 
for 24 hours. The digest was boiled for 5 minutes to 113 
inactivate the PNGase F and dialyzed in 2 mM 114 
 3 
Tris-HCl, pH 7.5. Desiaylation of GdA and GdF was 1 
performed using sialidase coated agarose beads 2 
(Sigma, MO, USA) in 1M Tris-HCl (pH 7) at 37
 o
C 3 
for 18 hours. The free sialic acid was removed by 4 
dialysis with 2 mM Tris-HCl, pH 7.5 at 4
o
C 5 
overnight. The success of desiaylation was verified 6 
by the decreased binding of the treated glycodelin to 7 
the lectin, wheat germ agglutinin which binds 8 
strongly to sialylated glycans and weakly to other 9 
glycoconjugates (22). The concentrations of the 10 
purified glycodelins were determined by a 11 
commercial protein assay kit (Bio-Rad, Hercules, 12 
USA). The purified glycodelins showed single bands 13 
in 12% gel sodium dodecyl sulfate polyacryamide 14 
gel (Figure 1). 15 
XTT cell viability/proliferation assay- Cell viability 16 
was determined by a colorimetric assay (Roche 17 
Diagnostics Co., Basel, Switerland) which measured 18 
the production of a color formazan end-product from 19 
a tetrazolium salt sodium 20 
3’-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-21 
methoxy-6-nitro) benzene sulfonic acid hydrate 22 
(XTT) from the viable cells. In this assay, XTT 23 
labeling mixture was freshly prepared by mixing 24 
XTT labeling reagent with electron coupling reagent 25 
at a ratio of 50:1. Fifty micro-litres of the labeling 26 
mixture was added to the cell culture 12 hours 27 
before the end of the incubation period. The 28 
absorbance was measured at 450 nm with λ 29 
correction at 595 nm (Infinite F200, Tecan, 30 
Männedorf, Switzerland). The cell suppression was 31 
expressed by the following equation: 32 
Suppression Index (%) = (Absorbance of glycodelin 33 
treated cells - Absorbance of blank) / (Absorbcance 34 
of control cells – Absorbance of blank) × 100% 35 
Cell death analysis by flow cytometry- After 36 
treatment the cells were labeled with Yo-Pro®-1 and 37 
propidium iodide (PI) for cell death analysis 38 
according to the manufacturer’s protocol (Invitrogen, 39 
Carlsbad, CA, USA). Briefly, 3x10
5
 cells were 40 
washed twice with PBS. Yo-Pro®-1 dye (1 μl) and 41 
PI (1 μl) in 0.5 ml of PBS was added into the cell 42 
suspension. After 15 minutes of incubation, the cells 43 
were analyzed immediately with a Coulter Epic Elite 44 
ESP flow cytometer (Beckman Coulter, Inc. 45 
Fullerton, CA, USA) equipped with an argon laser of 46 
488 nm. Fluorescence signal was measured using the 47 
525 nm and 610 nm band pass filters, and was 48 
analyzed by the Winlist software (Verity Software 49 
House, Topsham, ME, USA). Cells that were not 50 
stained were counted as viable. Cells labeled with 51 
Yo-Pro®-1 only were counted as apoptotic cells. 52 
Cells labeled with both Yo-Pro®-1 and PI were 53 
counted as necrotic cells. It should be noted that this 54 
cell population may also contained late apoptotic 55 
cells that were propidium iodide positive. 56 
Determination of IL-2 production by ELISA- The 57 
levels of IL-2 was measured from the culture 58 
supernatant of the treated cells according to the 59 
manufacturer protocol (BD Biosciences Pharmingen, 60 
San Diego, USA). In brief, capture antibody in 0.1 61 
M sodium carbonate buffer (pH 9.5) was coated on a 62 
96-well ELISA plate overnight at 4
 o
C. The wells 63 
were blocked with 200 μl of 10% FBS in PBS for 1 64 
hour and were incubated with 100 μl of culture 65 
medium overnight at 4
 oC. Then 100 μl of 66 
biotinylated detection antibody and avidin 67 
horseradish peroxidase conjugate mixture was added 68 
and incubated for 1 hour. Color development was 69 
achieved by enzymatic reaction using 70 
3.3’,5.5’-tetramethylbenzidine as substrate. The 71 
reaction was terminated by the addition of 50 μl of 72 
2M H2SO4. The absorbance was measured at 450 nm 73 
with λ correction of 595 nm. The wells were washed 74 
five times with 0.05% Tween-20 in PBS between 75 
each step.  76 
Lectin binding assays- Lectin binding assay (19) was 77 
used to study the glycosylation of glycodelins. 78 
Briefly, the wells in 96-well plate were coated with 79 
various lectins (10 μg/ml) overnight. Uncoated sites 80 
in the well were blocked by incubation with 100 μl 81 
of 5% casein in PBS for 3 hours with slow shaking. 82 
Glycodelins (7.5 pmol in 250 μl) were then added 83 
and incubated overnight at 4
o
C. After washing the 84 
wells twice with 0.05% Tween 20-TBS, monoclonal 85 
anti-glycodelin antibody (clone F43-7F9, 2.5 μg in 86 
200 μl) was added and the mixture was incubated for 87 
2 hours. The wells were washed 4 times and 100 μl 88 
of HRP conjugated anti-mouse IgG at a dilution of 89 
1:5000 (Sigma, St. Louis, MO, USA) was added. 90 
After 2 hours of incubation, the wells were washed 91 
and 100 μl per well of o-phenylenediamine (Sigma) 92 
was added. The OD490 was determined with a 93 
microplate reader (MR5000, Dynatech, Embrach, 94 
Switzerland). The assay was done at room 95 
temperature. The control wells contained BSA 96 
instead of glycodelin. 97 
Processing of the glycodelin N-glycans- Preparations 98 
of purified GdA, GdF and GdC (25-50 μg each) 99 
were used for all MALDI experiments and GC-MS 100 
analyses. Each of the 50 μg of GdA preparations was 101 
purified from separate pools of 500 ml of 102 
midtrimester amniotic fluid from 20 pregnant 103 
women whereas each of the 50 μg of GdF 104 
preparations was purified from separate pools of 2.5 105 
liters of follicular fluid from around 270 women 106 
enrolled in the assisted reproduction program.  107 
Preparations of 50 μg of GdC were purified from 108 
500 ml of cumulus matrix pooled from around 165 109 
cases of oocyte retrieval. 110 
 The purified glycodelins were initially 111 
subjected to reduction, carboxymethylation, and 112 
tryptic digestion before the N-glycans were released 113 
by PNGase-F (Roche Applied Science, Burgess Hill, 114 
 4 
UK) digestion. After that, the released N-glycans 1 
were purified by using a Sep-Pak C18 cartridge 2 
(Waters Corp, Hertfordshire, UK). Prior to mass 3 
spectrometric analyses, the purified native N-glycans 4 
were derivatised using the sodium hydroxide 5 
permethylation procedure. All of the above 6 
procedures were carried out as described previously 7 
(23). 8 
MS and MS/MS data acquisition of permethylated 9 
glycodelin N-glycans- MALDI- MS and MS/MS 10 
data were acquired using a 4800 MALDI-TOF/TOF 11 
(Applied Biosystems, Darmstadt, Germany) mass 12 
spectrometer. The collision energy was set to 1 kV, 13 
and argon was used as collision gas.  Samples were 14 
dissolved in 10 µl of methanol and 1 μl was mixed at 15 
a 1:1 ratio (v/v) with 2,5-dihydrobenzoic acid (20 16 
mg/ml in 70% methanol in water) as matrix. 17 
Analyses of MALDI data- The MS and MS/MS data 18 
were processed using Data Explorer 4.9 Software 19 
(Applied Biosystems, Warrington, UK). The mass 20 
spectra were baseline corrected (default settings) and 21 
noise filtered (with correction factor of 0.7), and 22 
then converted to ASCII format. The processed 23 
spectra were then subjected to manual assignment 24 
and annotation with the aid of a glycobioinformatics 25 
tool, GlycoWorkBench (24). Peak picking was done 26 
manually, and proposed assignments for the selected 27 
peaks were based on 
12
C isotopic composition 28 
together with knowledge of the biosynthetic 29 
pathways. The proposed structures were then 30 
confirmed by data obtained from MS/MS and 31 
linkage analysis experiments.  32 
GC-MS linkage analysis- Partially methylated alditol 33 
acetates were prepared and analysed by GC-MS as 34 
previously described (23). 35 
Biological characterization of different glycodelin 36 
isoforms- XTT assay and flow cytometry was used 37 
to study the effect of glycodelin on cell 38 
viability/proliferation and cell death, respectively. In 39 
brief, PBMC and cell lines including OE E6/E7 (25), 40 
NK92mi, K562, Jurkat, Hela, BeWo and RL95 were 41 
incubated with 0, 0.001, 0.01, 0.1 and 1 μg/ml of 42 
glycodelins or deglycosylated glycodelin in 100 μl 43 
of culture medium for 36 hours before XTT viability 44 
assay. Cell death analysis by flow cytometry was 45 
performed as described above in cells treated with 1 46 
μg/ml of glycodelins in 500 μl of culture medium for 47 
48 hours. For IL-2 analysis, cells were incubated 48 
with 1 μg/ml of glycodelins and stimulated by 5 49 
μg/ml of phytohaemagglutinin (PHA) in 500 μl of 50 
culture medium for 16 hours. The media after 51 
incubation were then collected. The cell debris in the 52 
conditioned media was removed by centrifugation at 53 
500 g for 5 minutes. The IL-2 production was 54 
determined by ELISA as described above. The 55 
viability of the cells at 16 hours was also determined 56 
by flow cytometry as described above. 57 
Determination of sialidase activity on cumulus cells- 58 
The Institutional Review Board of the University of 59 
Hong Kong/Hospital Authority Hong Kong West 60 
Cluster approved the protocol for collection and use 61 
of cumulus oophorus in this study. Cumulus-oocyte 62 
complexes were obtained from women who 63 
underwent treatment with intracytoplasmic sperm 64 
injection for male infertility. Human menopausal 65 
gonadotropin (Serono, Geneva, Switzerland) was 66 
used for ovarian stimulation after down-regulation 67 
with buserelin (26). The cumulus-oocyte complexes 68 
were dispersed in 1 ml of 0.1% hyalurondidase in 69 
human serum albumin supplemented G-MOPS 70 
medium (Vitrolife, Kungsbacka, Sweden) at 37
o
C. 71 
After digestion, cumulus cells were pelleted at 300 g 72 
for 5 minutes. The dispersed cumulus cells were 73 
then washed twice in TC-199 medium (Sigma) and 74 
resuspended to a final concentration of 4×10
6
 viable 75 
cells/ml. Trypan blue exclusion test was employed to 76 
determine the viability of the cells. They were then 77 
cultured in 2 ml of TC-199 medium supplemented 78 
with 20% fetal bovine serum as described (27).  79 
After 48 hours, sialidase activity on the cell 80 
surface of cumulus cells was determined using 81 
4-methylumbelliferyl N-acetylneuraminic acid 82 
(4MU-NANA; Sigma-Aldrich, St. Louis, MO, USA) 83 
as a substrate, according to previously described 84 
method (28). Briefly, after washing with fresh 85 
medium, the cells were incubated with 50 μmol/l of 86 
4MU-NANA in 1 ml of culture medium for 2-8 87 
hours at 37°C. The conditioned medium was then 88 
collected, centrifuged at 500 g for 15 minutes, and 89 
the liberated 4-methylumbelliferone in the 90 
supernatant was measured using a fluorometer with 91 
excitation at 340 nm and emission at 505 nm 92 
(Infinite F200, Tecan, Männedorf, Switzerland). 93 
Data analyses - All values were expressed as mean 94 
± S.E.M. (standard error mean). The data were 95 
compared by student’s t-test or ANOVA followed by 96 
a post-hoc test (Tukey’s test) to discern differences 97 
between individual groups. The data were analysed 98 
using SigmaStat 2.03 (Jandel Scientific, San Rafael, 99 
CA, USA). A P value below 0.05 was taken as 100 
significant. 101 
 102 
RESULTS 103 
 104 
Differential lectin binding properties of glycodelins - 105 
Glycodelin-A, -F, -S and -C were purified from 106 
amniotic fluid, follicular fluid, seminal plasma and 107 
cumulus matrix, respectively (Figure 1), and were 108 
analyzed for lectin binding. The lectin binding 109 
properties of glycodelins are shown in Table 1. 110 
Consistent with our previous data (5), GdF was 111 
characterized by significantly lower affinity to UAEI 112 
(P<0.05) and higher affinity to S-WGA (P<0.05), 113 
while GdS was characterized by a low affinity to 114 
 5 
WFA (P<0.05) when compared with other isoforms. 1 
GdA and GdF had significantly higher affinities to 2 
WGA and SNA than GdC and GdS (P<0.05). No 3 
significantly differences were found in ConA, PNA 4 
and RCA120 affinity between the glycodelin 5 
isoforms. 6 
Characterisation of the N-glycomes of GdA, GdC 7 
and GdF - Glycomic profiling was carried out using 8 
well documented methodologies (29,30). Briefly, 9 
samples were reduced, carboxymethylated,
 
digested 10 
with trypsin and the N-glycans were released by 11 
peptide
 
N-glycosidase F digestion and permethylated 12 
prior to MALDI-TOF profiling. When sample 13 
amounts permitted, MALDI-TOF/TOF sequencing 14 
and gas chromatography-MS linkage
 
analyses were 15 
additionally carried out. Analyses were done on two 16 
preparations of each of the purified glycodelins to 17 
allow assessment of reproducibility. The 18 
MALDI-TOF profiles for one of each of the GdA, 19 
GdC and GdF samples are shown in Figures 2 to 4, 20 
respectively. Spectra from the replicate batches are 21 
presented in Supplementary Figures S1 to S3, 22 
respectively. For clarity, not all components are 23 
given their m/z values and annotations in Figures 2 24 
to 4; complete assignments are presented in the 25 
expanded Supplementary Figures. The structures 26 
shown in the annotations were assigned from 27 
compositional information provided by the MALDI 28 
MS data, complemented by MALDI MS/MS and 29 
linkage data where available, taking into account 30 
biosynthetic considerations plus results of the earlier 31 
GdA study (6). Because of the limited amount of 32 
material, only a selection of the molecular ions 33 
observed in the MALDI-TOF spectra could be 34 
subjected to MS/MS experiments. Molecular ions 35 
analysed by MS/MS are flagged in the 36 
Supplementary Figures.  37 
 Important characteristics of these data are: (i) 38 
All of the glycodelin glycomes are immensely 39 
complex with many components of the same m/z 40 
value being mixtures of more than one type of 41 
structure. This trait is observed throughout the whole 42 
detectable mass range of m/z 1500-5200, 43 
(Supplementary Figures S1 to S3): from the lower 44 
mass region (e.g. m/z 1836, 2040, 2070, 2244, 2285, 45 
2459, and 2592) to the middle mass region (e.g. m/z 46 
2646, 2663, 2775, 2861, 3095) and high mass region 47 
(e.g. m/z 4267, 4512); (ii) Both lacNAc and 48 
lacdiNAc are present as antenna backbones in all 49 
three glycodelins and in many cases are substituted 50 
with fucose or sialic acid; (iii) Some of the glycans 51 
have compositions consistent with bisected 52 
structures and this was confirmed for GdA and GdC 53 
by the presence of 3,4,6-linked mannose in their 54 
linkage analysis data (Table 2); (iv) Biantennary 55 
glycans are the most abundant family in all 56 
glycodelins but a great diversity of tri- and 57 
tetraantennary structures are also present; (v) 58 
Sialylation levels differ markedly in the three 59 
isoforms. GdA is the most heavily sialylated, GdF 60 
has a similar glycan composition as GdA but with 61 
much lower sialylation, whilst GdC has the smallest 62 
repertoire of glycans carrying sialic acid. The 63 
duplicate batches gave broadly similar data, albeit 64 
with quantitative differences in some components. 65 
Whether these quantitative differences are an 66 
experimental artefact arising during sample handling 67 
prior to glycomic analysis or are due to differences 68 
between individual women remains to be established. 69 
With respect to the latter, it is significant that 70 
quantitative differences have previously been 71 
observed between individual GdA samples (31). 72 
Also it should be noted that GdC and GdF are low 73 
abundance glycodelins requiring the pooling of 74 
follicular fluid from almost 300 women for the 75 
preparation of a batch of 50 μg. (vi) Consistent with 76 
earlier observations (6), low levels of high mannose 77 
structures were observed in GdA and they were also 78 
detected as minor components of the GdC and GdF 79 
glycomes; (vii) All of the molecular ions observed in 80 
the original Fast Atom Bombardment (FAB) data for 81 
GdA ((6), Figure 2) are recapitulated in the current 82 
GdA data and abundances are comparable once the 83 
poor sensitivity at high mass of the FAB-MS 84 
methods of the 1990’s is taken into account. The 85 
MALDI experiments have additionally revealed a 86 
wealth of components above m/z 3000 which were 87 
not detected using the FAB ionization. Many of 88 
these glycans were unexpectedly found to carry the 89 
Sda epitope (NeuAcα2-3(GalNAcβ1-4)Gal) which 90 
gives characteristic fragment ions in MS/MS 91 
analysis (Figure 5 and (32), Figure 2B) and 92 
3,4-linked Gal in the linkage analysis 93 
(Supplementary Figure S4). The structures of 94 
Sda-containing glycans are shown in Supplementary 95 
Table S1; (ix) Sda containing glycans were also 96 
found in GdC and GdF (see Table S1). Interestingly 97 
those present in GdC are characterised by the 98 
absence of sialylation on other antennae. Indeed, 99 
careful scrutiny of the MALDI profiles allows us to 100 
conclude that the sialic acid on GdC is almost 101 
exclusively associated with the Sda epitope. 102 
Moreover, with the exception of this epitope, the 103 
GdC N-glycome appears to be the asialylated 104 
counterpart of the GdA glycome (see Discussion). 105 
Glycodelin-A and -F reduced viability/proliferation 106 
of lymphocytes - The effects of glycodelin treatment 107 
for 48 hours on the viability/proliferation of various 108 
cell lines are shown in Table 3. GdA and GdF at 109 
concentrations of ≥0.1 μg/ml significantly decreased 110 
(P<0.05) the viability of Jurkat and PBMCs, whereas 111 
GdS, GdC and deglycosylated glycodelin had no 112 
effect. At 1 µg/ml, GdA decreased the 113 
viability/proliferation of Jurkat cells and PBMC to 114 
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30.4±3.8% and 44.3±7.3% respectively. GdF at the 1 
same concentration reduced lymphocyte viability to 2 
a similar extent (Jurkat: 37.6±3.3%, p=0.002; PBMC: 3 
37.7±5.1%, P<0.001). None of the glycodelin 4 
glycoforms did affect the viability/proliferation of 5 
OE E6/E7, NK92mi, K562, Hela, BeWo and RL95 6 
cells at the tested concentrations (data not shown). 7 
Glycodelin-A and -F induced apoptotic and necrotic 8 
cell death of lymphocytes - The YoPro-PI assay was 9 
used to determine the proportion of viable, apoptotic 10 
and necrotic cells simultaneously in a sample 11 
(Figure 7 and Table 4). Treatment with 1 µg/ml of 12 
GdA significantly increased the apoptotic population 13 
of Jurkat cells from 6.4±0.3% to 33.4±5.3%, and the 14 
necrotic population from 6.4±0.3% to 22.7±12.1%. 15 
The corresponding values for GdF were 27.9±5.4% 16 
and 37.5±8.1%, respectively. 17 
GdA and GdF also caused cell death of PBMCs 18 
(Figure 7 and Table 4). GdA and GdF treatment for 19 
48 hours significantly increased the percentage of 20 
necrotic cells from 7.6±0.4% to 73.9±2.7% and 21 
75.8±1.9% and of apoptotic cells from 3.8±0.5% to 22 
8.9±0.9% and 8.7±0.9%, respectively. On the other 23 
hand, GdS, GdC and deglycosylated glycodelin had 24 
no significant effects on apoptosis and necrosis of 25 
Jurkat cells and PBMCs. 26 
Sialyation is important for activity of glycodelin-A 27 
on cell death of lymphocytes - Sialidase treatment 28 
decreased the sialic acid content of GdA and GdF as 29 
shown by a decrease in binding to wheat germ 30 
agglutinin (Supplementary Table S2). Desialyation 31 
abolished the ability of GdA and GdF in inducing 32 
cell death (Table 4).  33 
Glycodelin-A and -F suppress IL-2 secretion by 34 
lymphocytes- The effects of glycodelin treatment for 35 
16 hours on cytokine secretion of Jurkat cells and 36 
PHA-induced PBMCs were studied. None of the 37 
glycodelin isoforms affected cell viability within the 38 
treatment period (Figure 8). GdA and GdF 39 
significantly inhibited IL-2 secretion by Jurkat cells 40 
from 851.6±228.3 pg/ml (untreated control) to 41 
339.1±58.9 pg/ml (P<0.01) and 187.5±44.5 pg/ml 42 
(P<0.05), respectively. Other glycodelin isoforms 43 
and deglycosylated glycodelin had no effect. 44 
PBMCs were less sensitive to the inhibitory activity 45 
of GdA and GdF. The corresponding levels of IL-2 46 
were 925.9±53.1 pg/ml (P<0.01) and 857.1±117.0 47 
pg/ml, which were significantly lower (P<0.05) than 48 
the control (1355.8±102.3 pg/ml). GdC had a slight 49 
but significant inhibitory effect (P<0.05) on IL-2 50 
secretion in PBMCs.  51 
Cumulus cells possess sialidase activity - The 52 
sialidase activity in cumulus cells is shown in Figure 53 
9. The sialidase activity of the cumulus cells 54 
increased the production of the 55 
4-methylumbelliferone in a time-dependent manner 56 
and was significantly (P<0.05) higher than the 57 
corresponding medium control after 4 hours of 58 
incubation.  59 
 60 
DISCUSSION 61 
This is the first study to investigate the 62 
immunosuppressive activity of the two recently 63 
discovered glycodelin family members, GdF and 64 
GdC. Like GdA, GdF reduced cell 65 
viability/proliferation, induced cell death and 66 
reduced PHA-induced production of IL-2 from 67 
lymphocytes. The reduction in IL-2 production may 68 
be partly responsible for the decrease in cell 69 
viability/proliferation as IL-2 modulates 70 
proliferation of stimulated T cells (33). Our data on 71 
the immunosuppressive effects of GdA agree with 72 
previous reports that GdA inhibits lymphocyte 73 
growth by induction of cell death and reduction of 74 
IL-2 synthesis (18,34,35). Importantly, the 75 
immunosuppressive activity of GdA and GdF was 76 
glycosylation dependent and was abolished after 77 
deglycosylation and desialyation. 78 
Comparing the MALDI data for all three 79 
glycodelins, it is clear that there are both similarities 80 
and differences in their glycomes. The similarities 81 
lie in shared antennae sequences and branching 82 
patterns, whilst the differences are associated with 83 
variations in relative glycan abundances plus the 84 
absence of -6 linked sialic acid in GdC. GdA is 85 
the most heavily sialylated glycodelin as exemplified 86 
by the most abundant biantennary glycans observed 87 
in the MALDI profile (m/z 2646, 3007 and 3211, 88 
Figure 2) all of which are sialylated (Figure 6C). In 89 
contrast, GdF and GdC are both relatively poorly 90 
sialylated and their most abundant biantennary 91 
glycans are non-sialylated (Figure 6C). However, it 92 
is important to note that, like GdA, GdF carries 2-6 93 
linked sialic acid on a portion of its glycans 94 
(Supplementary Figure S3), whilst GdC is unique in 95 
lacking this type of sialylation. 96 
The shared outer arm 2-6 sialylation of GdA 97 
and GdF could explain the comparable 98 
immunosuppressive activities found in the present 99 
study, assuming that a small amount of an active 100 
glycoform is sufficient for conferring function.  101 
Similar observations have been reported for another 102 
glycoprotein with immunomodulatory properties, 103 
α1-acid glycoprotein (36). However, these 104 
observations do not exclude the possibility that GdA 105 
and GdF may suppress the lymphocyte activities by 106 
different glycans. Whether the similar 107 
immunosuppressive activities of GdA and GdF are 108 
due to the same or different glycan chain(s) is still an 109 
open question. 110 
In some other assays GdA and GdF have been 111 
found to behave differently. This may be a reflection 112 
of the lower degree of sialylation of GdF and/or 113 
differences in abundance of other sequences such as 114 
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fucosylated lacdiNAc. For example, only GdF but 1 
not GdA suppresses the progesterone-induced 2 
acrosome reaction (19). GdF also has higher sperm 3 
binding affinity compared to GdA (12,19,20).  4 
The advancement of MS technologies has led 5 
to the interesting discovery that there is an additional 6 
family of glycans in all the female glycodelins which 7 
was not characterised earlier, namely the Sda-capped 8 
family. The molecular ions of the most abundant 9 
members of this family are well above m/z 3000, and 10 
were therefore refractory to the mass spectrometry 11 
of the 1990’s; Even though smaller Sda-containing 12 
N-glycans are observed at m/z lower than 3000, they 13 
are of low abundance and are isobaric to other, more 14 
abundant, glycans. Moreover, the MS/MS methods 15 
equivalent to the TOF-TOF technology employed in 16 
the present work were not available when GdA was 17 
first characterised. Thus, the minor biantennary 18 
Sda-containing components now observed in the 19 
MALDI spectra (Figure 2A) were impossible to 20 
detect in the earlier FAB experiments (6). 21 
Cumulus cells can transform GdA and GdF to 22 
GdC (5). One of the important findings in this report 23 
is that the structures of the N-glycans of GdC are 24 
consistent with desialylation of the 2-6 sialylated 25 
antennae in GdA/GdF. This observation suggests 26 
that GdC may be a product of remodelling of 27 
GdA/GdF by the cumulus cells and that this process 28 
might be dominated by desialylation. Furthermore, 29 
the remodelling of GdA/GdF to GdC hypothesis is 30 
consistent with the present finding that cumulus cells 31 
possess sialidiase activity. Our unpublished 32 
observation has also shown that desialyation of GdA 33 
and GdF is associated with loss of sperm-zona 34 
pellucida binding inhibitory activity thereby 35 
resulting in comparable behaviour to GdC. 36 
 The sialidase of the cumulus cells is likely to 37 
have similar activity to the sialidase from Vibrio 38 
cholera (37) because it does not remove the sialic 39 
acid on the Sda epitope. To date, not much is known 40 
about the type of sialidase expressed on the surface 41 
of cumulus cells. Plasma membrane-associated 42 
sialidase (Neu3) is localized mainly on the cell 43 
surface, and has shown to be involved in the 44 
regulation of transmembrane signalling (38). 45 
However, since Neu3 is a glycolipid-specific 46 
sialidase which acts preferentially on ganglioside 47 
substrates, but have no activity against sialylated 48 
glycoproteins (Ha et al., 2004), glycodelins would be 49 
less likely the substrates of Neu3. Alternatively, the 50 
sialidase could be secreted by the cumulus cells as a 51 
soluble enzyme into the cumulus matrix. In this case, 52 
it would be similar to the glycan modifying enzymes 53 
in luminal fluid of rat epididymis that are known to 54 
be involved in sperm maturation (39). The recent 55 
discovery that a cell surface tumor suppressor called 56 
Klotho is a 2,6 specific sialidase and is known to be 57 
expressed in mouse cumulus (data accessible at 58 
NCBI GEO database (40), accession GSE4260 (41)) 59 
makes this molecule a possible candidate for our 60 
observed sialidase activity (42).  61 
The putative liberation of the sialic acid 62 
residues from GdA/GdF to form GdC may result in 63 
greater exposure of the Sda epitope. However to date, 64 
no receptor for this epitope has been identified. The 65 
Sda epitope is relatively rare in human and very little 66 
is known about its function. Nevertheless it is of 67 
interest that the Sda epitope in bovine pregnancy 68 
associated glycoproteins appears to be hormonally 69 
regulated (31). 70 
The new structural discoveries of the present 71 
work allow refinement of the hypothesis of the roles 72 
of glycodelin isoforms in human fertilisation (43). 73 
Glycodelin is synthesized in the granulosa cells of 74 
the late secondary follicle. During the periovulatory 75 
period, the sialidase present in cumulus cells use 76 
GdA and -F in the follicular fluid as substrate for the 77 
production of the GdC, which is then released into 78 
the extracellular matrix during cumulus expansion or 79 
shortly after ovulation. During cumulus penetration, 80 
GdC in the cumulus matrix displaces sperm-bound 81 
glycodelin isoforms and promotes the zona binding 82 
capacity of the penetrated spermatozoa. 83 
Carbohydrate interactions induce lymphocyte 84 
differentiation, maturation, activation, migration and 85 
responsiveness (44-46). In this study, both GdF and 86 
GdA were shown to possess a diversity of sialylated 87 
glycans and are immunosuppressive, while the 88 
non-sialylated GdS as well as GdC, which has 89 
Sda-restricted sialylation, lacked equivalent 90 
immunosuppressive activity. Importantly, the ability 91 
of GdA and GdF to induce lymphocyte cell death 92 
was abolished after desialyation, consistent with the 93 
reported crucial role of sialyation in the 94 
immunosuppressive activity of glycodelin (47). 95 
Sialic acid is an acidic monosaccharide that is 96 
usually the terminal sugar residue of N-glycan 97 
chains (48). The presence of sialic acid receptors on 98 
leukocytes is well recognized (49). Therefore, it is 99 
tempting to speculate that GdA and GdF might 100 
mediate their immunosuppressive effect through this 101 
type of receptor on lymphocytes. 102 
The immunosuppressive activity of glycodelin 103 
was abolished after deglycosylation in the present 104 
study. It has also been proposed that the apoptotic 105 
activity of glycodelin is associated with its protein 106 
backbone (50) based on the observation that GdA 107 
glycopeptide produced by trypsin digestion did not 108 
induce apoptosis (18) and mutation of both 109 
glycosylation sites (Asn-28 and Asn-68) of 110 
glycodelin yielded recombinant non-glycosylated 111 
glycodelin which retained anti-proliferative activity 112 
(50). The discrepancy in the immunosuppressive 113 
activity of deglycosylated glycodelin in the two 114 
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studies could be due to the deglycosylation method 1 
used; enzymatic deglycosylation in the present study 2 
and site-direct mutagenesis in the previous report. 3 
The former involved a denaturing step while the 4 
latter may change the protein configuration of the 5 
resulting molecule. Experiments using recombinant 6 
glycodelin from prokaryotes may help to solve the 7 
discrepancy. Recombinant glycodelin produced in E. 8 
coli has been shown to bind to monocytes, but not to 9 
T-cells and B-cells (51). However, glycosylation is 10 
essential for proper folding of glycoproteins (52-53), 11 
and deglycosylation strategies may therefore affect 12 
the binding and bioactivity of the deglycosylated 13 
molecules. 14 
The glycosylation of glycodelins is also 15 
important for their influence on human sperm 16 
behaviour. Deglycosylation abolishes the actions of 17 
glycodelins on capacitation, the acrosome reaction 18 
and zona pellucida binding ability (4,10,54). It has 19 
also been demonstrated that the glycans derived 20 
from GdA can modulate hormone production from 21 
trophoblast cells (55). 22 
In conclusion, the glycosylation of GdA, GdF 23 
and GdC show many similarities but there are some 24 
important differences, most notably in the level and 25 
type of sialylation. Evidence is presented that the 26 
glycans, particularly the sialic acid residues, are 27 
important in the immunosuppressive activities of 28 
glycodelin. Further understanding of the 29 
glycosylation of glycodelin isoforms, particularly 30 
their actions on lymphocytes may assist in the 31 
rational design of novel therapeutic strategies for 32 
immune-based disorders in reproduction. 33 
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FOOTNOTES 
 
Abbreviations used: MALDI, matrix assisted laser desorption/ionization; TOF, time of flight; 
MS, mass spectrometry; MS/MS, tandem mass spectrometry; GC, gas chromatography; 
PBMC, peripheral blood mononuclear cell; Sda epitope, (NeuAcα2-3(GalNAcβ1-4)Gal); 
XTT, sodium 3’-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro) benzene 
sulfonic acid hydrate; Gd, glycodelin; PHA, phytohemagglutinin;  
 
 
FIGURE LEGENDS 
 
Figure 1. Purity of purified glycodelins. The purity of 0.5 μg GdA, -F, -S, -C and 
deglycosylated glycodelin (De-Gd) were determined in a 12% sodium dodecyl sulfate 
polyacryamide gel electrophoresis and visualized by silver staining.. 
 
Figure 2. MALDI-TOF mass spectrum of GdA N-glycans: Panel A, m/z 1500-3500; Panel 
B, m/z 3500-5200. The N-glycans from purified glycodelin preparations were released by 
PNGase-F and permethylated (“Experimental Procedures”). A representative spectrum of GdA 
N-glycans is shown [batch (i)] and an additional sample analysed yielded similar data 
(Supplementary Figure S1). Data were acquired in the positive ion mode [M+Na]
+
. The figure 
on each right hand axis gives the total ion count for that panel of the overall spectrum. Peak 
assignments are based on 
12
C isotopic composition together with knowledge of the 
biosynthetic pathways, and structures were confirmed by MS/MS and linkage analyses. The 
sugar symbols are those employed by the Consortium for Functional Glycomics for the 
representation of glycan structures.  Structures shown outside a bracket have not been 
unequivocally defined. For simplicity, specific linkages are not assigned in the mass spectra 
and only one branching pattern for tri-antennary structures is shown. Therefore, the position of 
an antenna in a cartoon does not imply designation of a specific arm. MS/MS experiments 
showed that the biantennary glycans have the usual 3 and 6 arms as indicated in the cartoons. 
However we cannot rule out minor structures carrying both antennae on the 3 arm. Note the 
high level of sialylation and the presence of N-glycans with Sda antennae. 
 
Figure 3. MALDI-TOF mass spectrum of GdC N-glycans: Panel A, m/z 1500-2800; Panel 
B, m/z 2800-4500. A representative spectrum of GdC N-glycans is shown [batch (i)] and an 
additional sample analysed yielded similar data (Supplementary Figure S2). Data acquisition 
and peak assignments were carried out as for GdA (Figure 2). Note the lack of sialylation and 
the presence of N-glycans with Sda antennae. 
 
Figure 4. MALDI-TOF mass spectrum of GdF N-glycans: Panel A, m/z 1500-2800; Panel 
B, m/z 2800-4500. A representative spectrum GdF is shown [batch (i)] and an additional 
sample analysed yielded similar data (Supplementary Figure S3). Data acquisition and peak 
assignments were carried out as for GdA and GdC (Figures 2 and 3). 
 
Figure 5. Representative MALDI-TOF/TOF tandem mass spectra of Sda-containing 
glycodelin N-glycans: Panel A, MS/MS of the m/z 3253 component of GdA; Panel B, 
MS/MS of the m/z 3545 component of GdC. Signals present in Figures 2 and 3 were 
subjected to tandem MS and the resulting MS/MS data are shown. The fragment ions are 
consistent with the sequences shown in the inset. Fragmentation is usually favoured on the 
reducing side of HexNAc residues. The peaks which are labeled with an “x” are due to 
contaminating molecular or fragment ions from neighbouring peaks. The horizontal arrows on 
the spectra indicate losses from the molecular ion of the designated glycan moieties. Note the 
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characteristic fragment ion for the Sda epitope at m/z 1092 and the fragment ions at m/z 2184 (in 
Panel A), m/z 2476, 2013 and 1823 (in Panel B) for the loss of Sda-containing antenna. Other 
signals with potential Sda arrangements (Supplementary Figures S1 to S3) were analysed for 
GdA, GdC and GdF, and they yielded similar data.  
 
Figure 6. Major N-glycans of GdA/F and GdC: Panel A, antennae and cores of GdA and 
GdF; Panel B, antennae and cores of GdC; Panel C, structures of the major components 
corresponding to the three most abundant molecular ions in the biantennary regions of 
the MALDI profiles of GdA, GdC and GdF. The +/- annotations in the composite 
structures in A and B indicate that not all glycans carry the associated structural feature.  
 
Figure 7. Dot plot of glycodelin on PBMCs and Jurkat cells death after 48 hours 
treatment. Viable, necrotic and apoptotic cells were identified and quantified by bivariate 
Yo-Pro®-1/PI flow cytometry. Cells without stain were counted as  (green). Cells labed with 
Yo-Pro®-1 only were counted as apoptotic cells (blue). Cells labeled with both Yo-Pro®-1 
and PI were counted as necrotic cells (Red).  
 
Figure 8. Effect of glycodelin on IL-2 secretion and viability of PBMCs and Jurkat cells 
after 16 hours treatment. PBMCs primed by PHA (5 μg/ml) and Jurkat cells were incubated 
with 1 μg/ml of glycodelin for 16 hours. IL-2 secretion and Cell viability were quantified by 
ELISA and flow cytometry respectively. Data are mean ± S.E.M., N=4, * and ** P<0.05 and 
0.01 vs corresponding control, respectively  
 
Figure 9. Sialidase activity on the intact cumulus cells. Sialidase activity of intact cumulus 
cells was determined by incubation with 4MU-NANA at pH 7.4 for 2-8 hours at 37°C. The 
results represent the mean of three independent experiments ± S.E.M and are expressed as 
percentage of activity at time 0. *P<0.05 when compared to the corresponding control at the 
same time point. 
 
Table 1. Binding of lectins with glycodelin-C, -A, -S and -F. Data are presented as means ± 
S.E.M. (N=5). The control coated with 10000 ng/ml BSA instead of lectins had OD between 
0.07-0.13. 
a-b, c-d, e-f 
P<0.05 within the same row (ANOVA on rank). 
 
Table 2. GC-MS linkage analyses of partially methylated alditol acetates obtained from the 
PNGase F released N-glycans of glycodelin-A, glycodelin-F and glycodelin-C. Permethylated 
N-glycans were hydrolyzed, reduced, acetylated and analyzed by GC-MS (“Experimental 
Procedures”). Note the presence of the 3,4-linked galactose which provides evidence for the 
Sda epitope, and 3,4,6-linked mannose for bisecting GlcNAc. 
 
Table 3. Effect of Glycodelins on viability of Jurkat and PBMCs by XTT assay. Cells of 
3x10
4
 were incubated with 0.001, 0.01, 0.1 and 1 μg/ml of glycodelins for 36 hours, XTT 
labeling mixture was added 12 hours before measurement. Percentage stimulation (%) = (Abs 
Gd - Abs blank) / (Abs control–Abs blank) x 100%. Data are mean ± S.E.M, N=8. P values 
are shown for significant differences as compared to control without treatment (One-way 
ANOVA).  
 
Table 4. Effect of deglycosylation and desialyation of GdA on cell death of Jurkat and 
PBMCs. Jurkat cells and PBMCs were incubated with 1 μg/ml of glycodelin A, F, S, C and 
deglycosylated glycodelin (De-Gd). Viable, necrotic and apoptotic cells were identified and 
quantified by bivariate Yo-Pro®-1/PI flow cytometry. Cells without stain were counted as 
viable cell. Cells labeled with Yo-Pro®-1 only were counted as apoptotic cells. Cells labeled 
with both Yo-Pro®-1 and PI was counted as necrotic cells. Data are mean ± S.E.M, N=4, * 
and ** P<0.01 and 0.001, P values are shown for significant differences as compared to 
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control without treatment (student’s t-test). 
 
Supplementary Figure S1. MALDI-TOF mass spectra of N-glycans from two GdA 
preparations. Regions from the MALDI MS spectra for both batches are expanded for clarity. 
Data are presented in sets of spectra with the upper panel of each subfigures being the first 
batch of GdA [GdA - batch (i); 50 µg starting material] and the lower panel, the second batch 
[GdA - batch (ii); 50 µg starting material]. Subfigure S1-A, m/z 1560-2000;  Subfigure S1-B, 
m/z 2000-2300; Subfigure S1-C, m/z 2300-2600; Subfigure S1-D, m/z 2600-2900; Subfigure 
S1-E, m/z 2900-3200; Subfigure S1-F, m/z 3200-3500; Subfigure S1-G, m/z 3500-3800; 
Subfigure S1-H, m/z 3800-4090; Subfigure S1-I, m/z 4090-4550; Subfigure S1-J, m/z 
4500-5200 (GdA - batch (i) only because batch (ii) appeared to contain a little less sample and 
signal to noise was poor above m/z 4500).  
 The glycodelin N-glycans were released by PNGase F, permethylated, and subsequently 
subjected to Sep-Pak cleanup ("Experimental Procedures"). Data were acquired in the positive 
ion mode [M+Na]
+
. Peak assignments are based on 
12
C isotopic composition together with 
knowledge of the biosynthetic pathways, and structures were confirmed by MS/MS and 
linkage analyses. The assignments for the peaks with boxed m/z values were confirmed by 
MS/MS.  The sugar symbols are those employed by the Consortium for Functional 
Glycomics for the representation of glycan structures. Structures shown outside a bracket 
have not been unequivocally defined. For simplicity, specific linkages are not assigned in the 
mass spectra and only one branching pattern for tri-antennary structures is shown. Therefore, 
the position of an antenna in a cartoon does not imply designation of a specific arm. Peaks 
which are labelled with an "x" are due to known contaminants. 
 
Supplementary Figure S2. MALDI-TOF mass spectra of N-glycans from two GdC 
preparations. Regions from the MALDI MS spectra for both batches are expanded for clarity. 
Data are presented in sets of spectra with the upper panel of each subfigures being the first 
batch of GdC [GdC - batch (i); 50 µg starting material] and the lower panel, the second batch 
[GdC - batch (ii); 50 µg starting material]. Subfigure S2-A, m/z 1560-2000;  Subfigure S2-B, 
m/z 2000-2300; Subfigure S2-C, m/z 2300-2600; Subfigure S2-D, m/z 2600-2900; Subfigure 
S2-E, m/z 2900-3200; Subfigure S2-F, m/z 3200-3500; Subfigure S2-G, m/z 3500-3800; 
Subfigures S2-H (m/z 3800-4090) and S2-I (m/z 4090-4500) are data only from GdC - batch (i) 
because batch (ii) appeared to contain a little less sample and signal to noise was poor above 
m/z 3600. For experimental details see Figure S1. 
 
Supplementary Figure S3. MALDI-TOF mass spectra of N-glycans from two GdF 
preparations. Regions from the MALDI MS spectra for both batches are expanded for clarity. 
Data are presented in sets of spectra with the upper panel of each subfigures being the first 
batch of GdF [GdF - batch (i); 50 µg starting material] and the lower panel, the second batch 
[GdF - batch (ii); 25 µg starting material]. Subfigure S3-A, m/z 1560-2000;  Subfigure S3-B, 
m/z 2000-2300; Subfigure S3-C, m/z 2300-2600; Subfigure S3-D, m/z 2600-2900; Subfigure 
S3-E, m/z 2900-3200; Subfigure S3-F, m/z 3200-3500; Subfigures S3-G (m/z 3500-3800), 
S3-H (m/z 3800-4090) and S3-I (m/z 4090-4500) are data only from GdF - batch (i) because 
the batch (ii) had half the amount of sample compared to batch (i) and signal to noise was 
poor above m/z 3500. For experimental details see Figure S1. 
 
Supplementary Figure S4. Electron impact mass spectra (EI-MS) of the partially 
methylated alditol acetate (PMAA) derived from 3,4-linked galactose, which provides 
the evidence for the Sda epitope: Upper Panel, GdA; Lower Panel, GdC. GC-MS linkage 
analyses of partially methylated alditol acetates obtained from the PNGase-F released 
N-glycans of GdA and GdC. Permethylated N-glycans were hydrolyzed, reduced, acetylated 
and analyzed by GC-MS (“Experimental Procedures”). The retention time on the capillary GC 
column and the fragment ions observed in the EI-MS spectra are used to identify the 
3,4-linked galactose. Characteristic fragment ions of 3,4-linked galactose PMAA shown in the 
inset. 
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Supplementary Table 1.  The structures of the Sda-containing glycans. The table is 
tabulated from the signals observed in the mass spectra (Supplementary Figures S1 to S3). 
The m/z values are rounded up to whole numbers for the ease of comparison. Values which 
are more than m/z 3200 are adjusted by the addition of m/z 1 to make the rounding more 
accurate. 
 
Supplementary Table S2. Binding of GdA with or without sialidase treatment to wheat germ 
agglutinin (WGA).  
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Table 1 
 
Lectin  
[specificity] 
Lectin-immunoassay at OD490 (Mean ± SEM) 
GdC GdF GdA GdS 
     Peanut agglutinin (PNA)   
[-Gal(1-3)GalNAc] 
0.18 ± 0.02
 
0.12 ± 0.01 0.07 ± 0.01 0.10 ± 0.01
 
Succinylated wheat germ agglutinin (S-WGA)  
[GlcNAc or its oligomer] 
0.62 ± 0.05
a
 1.34 ± 0.06
b,c
 0.48 ± 0.04
d 
0.32 ± 0.04
d 
Concanavalin A (ConA)   
[-Man, -Glc] 
1.45 ± 0.08 1.20 ±0.16 1.19 ±0.18 1.33 ± 0.15 
Wisteria floribunda agglutinin (WFA) 
[GalNAc] 
1.47 ± 0.15
a
 0.92 ± 0.05
b,c
 1.04 ± 0.08
b,e
 0.29 ± 0.02
b,d,f
 
Ricinus communis agglutinin (RCA120) 
[-Gal] 
1.16 ± 0.12 0.80 ± 0.12 0.98 ±0.15 1.20 ± 0.17 
Sambucus nigra bark agglutinin (SNA)  
[-NeuNAc(2-6)Gal/GalNAc] 
0.52 ± 0.04
a
 1.65 ± 0.18
b,c
 1.71 ± 0.18
b,e
 0.39 ± 0.07
d,f 
Wheat germ agglutinin (WGA) 
[(GlcNAc)2, NeuNAc] 
0.48 ± 0.09
a
 1.26 ± 0.15
b,c
 1.02 ± 0.14
b,e
 0.27 ± 0.03
d,f 
Ulex europaeus agglutinin (UEAI) 
[-L-fuc] 
1.56 ± 0.10
a
 0.90 ± 0.12
b,c
 1.28 ± 0.07
d 
1.48 ± 0.13
d
 
     
Data are presented as means ± S.E.M. (N=5). 
The control coated with 10000 ng/ml BSA instead of lectins had OD between 0.07-0.13. 
a-b, c-d, e-f 
P<0.05 within the same row (ANOVA on rank). 
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Table 2 
 
Characteristic Fragment Ions Assignment 
Elution Time (Mins) 
GdA GdC 
    
115, 118, 131, 162, 175 terminal fucose 17.47 16.97 
102, 118, 129, 145, 161, 162, 205 terminal mannose 18.98 18.47 
102, 118, 129, 145, 161, 162, 205 terminal galactose 19.23 18.73 
129, 130, 161, 190 2-linked mannose 20.14 19.62 
118, 129, 161, 234 3-linked mannose 20.32 19.79 
118, 129, 161, 234 3-linked galactose 20.43 19.89 
99, 102, 118, 129, 162, 189, 233 6-linked galactose 20.95 Not detected 
118, 305 3,4-linked galactose 21.10 20.56 
130, 190, 233 2,4-linked mannose 21.34 20.78 
129, 130, 189, 190 2,6-linked mannose 21.74 21.17 
118, 129, 189, 234 3,6-linked mannose 21.89 21.33 
118, 333 3,4,6-linked mannose 22.35 21.78 
117, 159, 203, 205 terminal GlcNAc 22.83 22.50 
117, 159, 203, 205 terminal GalNAc 23.27 22.62 
117, 159, 233 4-linked GlcNAc 23.72 23.12 
117, 159, 346 3,4-linked GlcNAc 24.58 23.98 
117, 159, 203, 233 6-linked GalNAc 24.71 Not detected 
117, 159, 261 4,6-linked GlcNAc 25.02 24.40 
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Table 3 
 
  Suppression Index (S.I. ± SEM) 
 
Glycodelin 
(μg/ml) 
GdA GdF GdS GdC De-Gd 
       
Jurkat 0.001 102.1 ± 2.3 108.5 ± 3.1 100.0 ±2.2 98.9 ± 0.4 99.9 ± 0.7 
 0.01 97.3 ± 5.6 94.5 ± 6.3 99.6 ±3.2 99.2 ± 1.6 98.3 ± 1.0 
 0.1 
59.6 ± 3.8 
p<0.001 
66.5 ± 10.2 
p<0.001 
101.0 ±3.0 94.4 ± 3.9 101.3 ± 0.8 
 1 
30.4 ± 3.8 
p=0.026 
37.6± 3.3 
p=0.002 
97.0 ±2.3 99.7 ± 3.3 100.9 ± 1.3 
       
PBMCs 0.001 99.2 ± 3.5 104.0 ± 1.8 104. ± 2.3 106.6 ± 4.6 106.6 ± 5.0 
 0.01 97.6 ± 5.8 99.9 ± 5.6 108.2 ± 5.4 110.1 ± 6.1 103.2 ± 1.2 
 0.1 
73.2 ± 8.0 
p=0.017 
75.4 ± 6.1 
p<0.001 
108.0 ± 5.3 111.3 ± 5.4 100.6 ± 4.7 
 1 
44.3 ± 7.3 
p<0.001 
37.7 ± 5.1 
p<0.001 
96.5 ± 3.4 101.9 ± 3.8 105.6 ± 3.6 
       
Data are mean ± S.E.M (N=8). 
Suppression Index (%) = (Abs Gd - Abs blank) / (Abs control–Abs blank) x 100%  
P values were shown for significant differences as compared to control without treatment (One-way 
ANOVA). 
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Table 4 
 
 Control GdA GdF GdS GdC 
Deglycosylated 
Gd 
Desialyated 
GdA 
De-sialyated 
GdF 
Jurkat         
Viable 87.3 ± 0.4% 22.7 ± 12.1% * 34.6 ± 13.5% * 86.3 ± 1.0% 86.3 ± 1.3% 84.1 ± 1.9% 82.9 ± 1.6 87.9 ± 0.7 
Apoptosis 6.4 ± 0.3% 33.4 ± 5.3% * 27.9 ± 5.4% * 6.5 ± 0.5% 6.6 ± 0.7% 7.5 ± 1.1% 9.3 ± 1.4 6.3 ± 1.0 
Necrosis 6.4 ± 0.3% 22.7 ± 12.1% * 37.5 ± 8.1% * 7.2 ± 0.5% 7.1 ± 0.7% 8.4 ± 0.9% 7.7 ± 1.0 5.6 ± 1.6 
         
PBMCs         
Viable 88.3 ± 0.9% 15.6 ± 1.9% ** 14.2 ± 1.2% ** 87.6 ± 0.3% 83.2 ± 2.5% 82.5 ± 2.9% 83.4 ± 1.6 82.9 ± 1.6 
Apoptosis 3.8 ± 0.5% 8.9 ± 0.9% ** 8.7 ± 0.9% ** 3.0 ± 0.2% 4.1 ± 0.7% 4.9 ± 1.1% 9.8 ± 1.7 9.3 ± 1.4 
Necrosis 7.6 ± 0.4% 73.9 ± 2.7% ** 75.8 ± 1.9% ** 8.9 ± 0.3% 12.0 ± 1.8% 11.8 ± 1.6% 6.8 ± 1.0 7.7 ± 1.0 
         
Data are mean ± S.E.M (N=4). 
* and ** p< 0.01 and 0.001, P values were shown for significant differences as compared to control without treatment (Student’s t-test). 
 
